<p>Acrivon Therapeutics, Inc.（纳斯达克代码：ACRV - 获取免费报告）首席运营官 Eric Devroe 于 1 月 13 日（星期二）购买了 10,000 股该公司的股票。每股购买价格为 1.72 美元，总交易额为 17,200.00 美元。购买后，首席运营官直接持有公司 75,308 股，价值约为 129,529.76 美元。这代表其持股增加了 15.31%。此次收购已在与 SEC 的法律文件中披露，您可以通过此链接访问。</p>
<p>获取 <strong>Acrivon Therapeutics</strong> 的提醒：</p>
<h2>Acrivon Therapeutics 股票表现</h2>
<p>在周四的午盘交易中，纳斯达克 ACRV 的股票上涨了 0.04 美元，达到了 1.87 美元。该公司交易了 1,214,845 股，而其平均交易量为 6,233,631 股。Acrivon Therapeutics, Inc. 的 12 个月低点为 1.05 美元，12 个月高点为 8.00 美元。该公司的市值为 5902 万美元，市盈率为-0.88，贝塔值为 1.73。该股票的 50 日移动平均价格为 2.30 美元，200 日移动平均价格为 1.81 美元。</p>
<p>Acrivon Therapeutics（纳斯达克：ACRV - 获取免费报告）最近于 11 月 13 日发布了季度财报。公司报告本季度每股收益为（0.47 美元），超出市场共识预期的（0.57 美元）0.10 美元。整体来看，股票分析师预计 Acrivon Therapeutics, Inc.在当前年度的每股收益为-2.49 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>几家券商最近对 ACRV 进行了评估。HC Wainwright 在 11 月 25 日的研究报告中重申了对 Acrivon Therapeutics 的 “买入” 评级，并给出了 19.00 美元的目标价。Wall Street Zen 在 1 月 10 日的研究报告中将 Acrivon Therapeutics 的股票评级从 “持有” 下调至 “卖出”。Piper Sandler 在 1 月 9 日的研究报告中将 Acrivon Therapeutics 的目标价从 6.00 美元上调至 8.00 美元，并给予公司 “增持” 评级。最后，Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 Acrivon Therapeutics 的 “卖出（d-）” 评级。五位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Acrivon Therapeutics 目前的平均评级为 “适度买入”，共识目标价为 11.67 美元。</p>
<p><strong>查看我们对 Acrivon Therapeutics 的最新股票分析</strong></p>
<h2>对 Acrivon Therapeutics 的对冲基金看法</h2>
<p>一些对冲基金最近买入和卖出了该公司的股票。Focus Partners Wealth 在第三季度购买了 Acrivon Therapeutics 的新股份，价值约为 36,000 美元。Algert Global LLC 在第三季度购买了 Acrivon Therapeutics 的新股份，价值约为 81,000 美元。Two Sigma Investments LP 在第三季度将其在 Acrivon Therapeutics 的持股增加了 76.2%。Two Sigma Investments LP 现在持有 319,205 股该公司的股票，价值为 578,000 美元，此前在上个季度又购买了 138,033 股。瑞银集团（UBS Group AG）在第三季度将其在 Acrivon Therapeutics 的持股增加了 150,057.8%。瑞银集团现在持有 683,218 股该公司的股票，价值为 1,237,000 美元，此前在上个季度又收购了 682,763 股。最后，Jane Street Group LLC 在第二季度购买了 Acrivon Therapeutics 的新股份，价值约为 371,000 美元。机构投资者持有该公司 71.62% 的股票。</p>
<h2>Acrivon Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Acrivon Therapeutics 纳斯达克：ACRV 是一家临床阶段的生物技术公司，专注于开发用于治疗 RAS 驱动癌症的固定肽治疗药物。其专有平台旨在增强肽分子的稳定性、细胞渗透性和靶向特异性，从而使得传统上难以用小分子药物或生物制剂抑制的蛋白质 - 蛋白质相互作用得以干扰。</p>
<p>该公司的主要开发候选药物是一种选择性靶向 KRAS G12C 突变的碳氢化合物固定肽，目前正在进行早期临床试验。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Acrivon Therapeutics</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>执行令 14330：特朗普最大的一次</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元于 Acrivon Therapeutics 吗？</h2>
<p>在您考虑 Acrivon Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Acrivon Therapeutics 并不在名单上。</p>
<p>虽然 Acrivon Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ACRV

<p>Acrivon Therapeutics 首席运营官 Eric Devroe 以每股 1.72 美元的价格购买了 10,000 股公司股票，总计 17,200 美元。这次收购使他的持股增加到 75,308 股，估值约为 129,529.76 美元，标志着他的持仓增加了 15.31%。该交易已向美国证券交易委员会（SEC）披露。Acrivon Therapeutics 的股票交易价格为 1.87 美元，市值为 5,902 万美元。分析师对该股票的评级不一，普遍目标价为 11.67 美元</p>

<p>Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) COO Eric Devroe bought 10,000 shares of the business's stock in a transaction dated Tuesday, January 13th. The shares were bought at an average cost of $1.72 per share, for a total transaction of $17,200.00. Following the purchase, the chief operating officer directly owned 75,308 shares in the company, valued at approximately $129,529.76. This represents a 15.31% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.</p>
<div class="lb-trans"><p>Acrivon Therapeutics, Inc.（纳斯达克代码：ACRV - 获取免费报告）首席运营官 Eric Devroe 于 1 月 13 日（星期二）购买了 10,000 股该公司的股票。每股购买价格为 1.72 美元，总交易额为 17,200.00 美元。购买后，首席运营官直接持有公司 75,308 股，价值约为 129,529.76 美元。这代表其持股增加了 15.31%。此次收购已在与 SEC 的法律文件中披露，您可以通过此链接访问。</p>
</div><p>Get <strong>Acrivon Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Acrivon Therapeutics</strong> 的提醒：</p>
</div><h2>Acrivon Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Acrivon Therapeutics 股票表现</h2>
</div><p>Shares of NASDAQ ACRV traded up $0.04 during midday trading on Thursday, hitting $1.87. 1,214,845 shares of the company traded hands, compared to its average volume of 6,233,631. Acrivon Therapeutics, Inc. has a 12-month low of $1.05 and a 12-month high of $8.00. The firm has a market cap of $59.02 million, a P/E ratio of -0.88 and a beta of 1.73. The stock has a 50-day moving average price of $2.30 and a 200 day moving average price of $1.81.</p>
<div class="lb-trans"><p>在周四的午盘交易中，纳斯达克 ACRV 的股票上涨了 0.04 美元，达到了 1.87 美元。该公司交易了 1,214,845 股，而其平均交易量为 6,233,631 股。Acrivon Therapeutics, Inc. 的 12 个月低点为 1.05 美元，12 个月高点为 8.00 美元。该公司的市值为 5902 万美元，市盈率为-0.88，贝塔值为 1.73。该股票的 50 日移动平均价格为 2.30 美元，200 日移动平均价格为 1.81 美元。</p>
</div><p>Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.10. As a group, equities analysts expect that Acrivon Therapeutics, Inc. will post -2.49 earnings per share for the current year.</p>
<div class="lb-trans"><p>Acrivon Therapeutics（纳斯达克：ACRV - 获取免费报告）最近于 11 月 13 日发布了季度财报。公司报告本季度每股收益为（0.47 美元），超出市场共识预期的（0.57 美元）0.10 美元。整体来看，股票分析师预计 Acrivon Therapeutics, Inc.在当前年度的每股收益为-2.49 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several brokerages recently weighed in on ACRV. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $19.00 price target on shares of Acrivon Therapeutics in a research note on Tuesday, November 25th. Wall Street Zen downgraded shares of Acrivon Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, January 10th. Piper Sandler lifted their price target on shares of Acrivon Therapeutics from $6.00 to $8.00 and gave the company an &#34;overweight&#34; rating in a research report on Friday, January 9th. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Acrivon Therapeutics in a research note on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Acrivon Therapeutics currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $11.67.</p>
<div class="lb-trans"><p>几家券商最近对 ACRV 进行了评估。HC Wainwright 在 11 月 25 日的研究报告中重申了对 Acrivon Therapeutics 的 “买入” 评级，并给出了 19.00 美元的目标价。Wall Street Zen 在 1 月 10 日的研究报告中将 Acrivon Therapeutics 的股票评级从 “持有” 下调至 “卖出”。Piper Sandler 在 1 月 9 日的研究报告中将 Acrivon Therapeutics 的目标价从 6.00 美元上调至 8.00 美元，并给予公司 “增持” 评级。最后，Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 Acrivon Therapeutics 的 “卖出（d-）” 评级。五位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Acrivon Therapeutics 目前的平均评级为 “适度买入”，共识目标价为 11.67 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Acrivon Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Acrivon Therapeutics 的最新股票分析</strong></p>
</div><h2>Hedge Funds Weigh In On Acrivon Therapeutics</h2>
<div class="lb-trans"><h2>对 Acrivon Therapeutics 的对冲基金看法</h2>
</div><p>A number of hedge funds have recently bought and sold shares of the company. Focus Partners Wealth bought a new stake in Acrivon Therapeutics during the 3rd quarter valued at about $36,000. Algert Global LLC purchased a new stake in shares of Acrivon Therapeutics during the third quarter valued at approximately $81,000. Two Sigma Investments LP grew its holdings in shares of Acrivon Therapeutics by 76.2% during the third quarter. Two Sigma Investments LP now owns 319,205 shares of the company's stock valued at $578,000 after buying an additional 138,033 shares during the last quarter. UBS Group AG increased its position in shares of Acrivon Therapeutics by 150,057.8% during the third quarter. UBS Group AG now owns 683,218 shares of the company's stock valued at $1,237,000 after acquiring an additional 682,763 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in Acrivon Therapeutics in the 2nd quarter worth approximately $371,000. Institutional investors own 71.62% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近买入和卖出了该公司的股票。Focus Partners Wealth 在第三季度购买了 Acrivon Therapeutics 的新股份，价值约为 36,000 美元。Algert Global LLC 在第三季度购买了 Acrivon Therapeutics 的新股份，价值约为 81,000 美元。Two Sigma Investments LP 在第三季度将其在 Acrivon Therapeutics 的持股增加了 76.2%。Two Sigma Investments LP 现在持有 319,205 股该公司的股票，价值为 578,000 美元，此前在上个季度又购买了 138,033 股。瑞银集团（UBS Group AG）在第三季度将其在 Acrivon Therapeutics 的持股增加了 150,057.8%。瑞银集团现在持有 683,218 股该公司的股票，价值为 1,237,000 美元，此前在上个季度又收购了 682,763 股。最后，Jane Street Group LLC 在第二季度购买了 Acrivon Therapeutics 的新股份，价值约为 371,000 美元。机构投资者持有该公司 71.62% 的股票。</p>
</div><h2>Acrivon Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Acrivon Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Acrivon Therapeutics NASDAQ: ACRV is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.</p>
<div class="lb-trans"><p>Acrivon Therapeutics 纳斯达克：ACRV 是一家临床阶段的生物技术公司，专注于开发用于治疗 RAS 驱动癌症的固定肽治疗药物。其专有平台旨在增强肽分子的稳定性、细胞渗透性和靶向特异性，从而使得传统上难以用小分子药物或生物制剂抑制的蛋白质 - 蛋白质相互作用得以干扰。</p>
</div><p>The company's lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.</p>
<div class="lb-trans"><p>该公司的主要开发候选药物是一种选择性靶向 KRAS G12C 突变的碳氢化合物固定肽，目前正在进行早期临床试验。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Acrivon Therapeutics</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Acrivon Therapeutics</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>执行令 14330：特朗普最大的一次</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Acrivon Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元于 Acrivon Therapeutics 吗？</h2>
</div><p>Before you consider Acrivon Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Acrivon Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acrivon Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Acrivon Therapeutics 并不在名单上。</p>
</div><p>While Acrivon Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Acrivon Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Acrivon Therapeutics (NASDAQ:ACRV) 的首席运营官购入了价值 17,200.00 美元的股票